3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
37
Precursor Cell Lymphoblastic Leukemia-Lymphoma
35
Lymphoma, Large B-Cell, Diffuse
28
Multiple Myeloma
26
Lymphoma
26
Lymphoma, Non-Hodgkin
21
Leukemia, Myeloid, Acute
21
Leukemia, Lymphocytic, Chronic, B-Cell
21
Neoplasms
20
Myelodysplastic Syndromes
19
Lymphoma, Follicular
18
Recurrence
16
Lymphoma, B-Cell
16
Leukemia
16
Burkitt Lymphoma
16
Lymphoma, Mantle-Cell
15
Triple Negative Breast Neoplasms
14
Ovarian Neoplasms
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Neuroblastoma
10
Lymphoma, B-Cell, Marginal Zone
10
Hodgkin Disease
10
Sarcoma
8
Melanoma
8
Medulloblastoma
8
Rhabdomyosarcoma
7
Myeloproliferative Disorders
7
Leukemia, Biphenotypic, Acute
7
Carcinoma, Non-Small-Cell Lung
6
Brain Neoplasms
6
Interventions
cabozantinib
2
pembrolizumab
1
lenvatinib
1
fludarabine
1
Selenomethionine
1
Nivolumab
1
Ipilimumab
1
Everolimus
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Clear-cell metastatic renal cell carcinoma
×
Cyclophosphamide
×
Clear all
NCT04696731
2025-09-25
TRAVERSE
Allogene Therapeutics
Phase 1
Active not recruiting
120 enrolled